IONQ Earnings Prediction
The chart below shows how IONQ performed 10 days before and after its earnings report, based on data from the past quarters. Typically, IONQ sees a -0.79% change in stock price 10 days leading up to the earnings, and a +2.11% change 10 days following the report. On the earnings day itself, the stock moves by -0.91%. This data can give you a slight idea of what to expect for the next quarter's release.
IONQ Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
11.71M
91.78%
-5.56%
Gross Margin
9.91%
207.48%
23.57%
Operating Margin
-661.85%
-25.78%
54.45%
Net Margin
-1725.00%
151.36%
307.46%
EPS
-0.93
-365.00%
287.50%
No Data Available
IONQ Earnings Analysis
IONQ Inc Corporation (IONQ.N) Earnings Conference Call
Positive
Record Bookings Growth: 2024 was IonQ's best year ever, with full-year bookings growing by 47% to $95.6 million.
Revenue Surges Exceeding Expectations: Revenue nearly doubled, achieving $43.1 million for the year and $11.7 million for the fourth quarter, both exceeding guidance.
Quantum Networking Enhancement: IonQ acquired Qubitekk, enhancing its capabilities in quantum networking and distributed quantum computing.
Strategic Acquisition Announcement: IonQ signed a definitive agreement to acquire a controlling stake in ID Quantique, consolidating a significant portfolio of patents and business.
Product Launch Success: The company delivered its first Forte enterprise system to QuantumBasel and the Air Force Research Lab, showcasing its product capabilities.
Strategic Partnerships Progressing: IonQ's collaboration with AstraZeneca on drug discovery and with Ansys on computer-aided engineering is progressing well, indicating strong partnerships.
Technical Progress Milestone: The company is on track to achieve AQ 64 by the end of the year, demonstrating significant technical progress.
Leadership Transition and Growth: Leadership changes, including the appointment of Niccolo de Masi as CEO, are expected to drive growth and strategic direction.
Quantum Networking Investment: IonQ launched a $500 million at-the-market facility to support its growth in quantum networking and applications.
2025 Revenue Guidance: Revenue guidance for 2025 is projected between $75 million to $95 million, indicating continued growth momentum.
Negative
Increased Net Loss: Net loss of $202 million in Q4 2024, compared to $41.9 million in the prior year period, indicating a significant increase in losses.
Net Loss Increase: Full-year net loss of $331.6 million for 2024 versus $157.8 million in 2023, showing a worsening financial situation year-over-year.
Rising Operational Costs: Total operating costs and expenses were $89.2 million in Q4 2024, up 47% from $60.6 million in the prior year period, indicating rising operational costs.
Rising Administrative Costs: General and administrative costs in Q4 were $29.7 million, up 94% from $15.3 million in the prior year period, reflecting unsustainable growth in overhead expenses.
Stock-Based Compensation Increase: Stock-based compensation increased to $106.9 million for the full-year 2024, up from $69.7 million in 2023, which could indicate potential issues with employee retention or compensation strategy.
Deteriorating Operational Efficiency: Adjusted EBITDA loss for Q4 was $32.8 million, compared to a $20 million loss in the prior year period, indicating deteriorating operational efficiency.
Projected EBITDA Loss: Projected adjusted EBITDA loss of $120 million for the full-year 2025 at the midpoint of revenue guidance, suggesting continued financial strain ahead.
IONQ FAQs
How does IONQ typically perform around its earnings report dates?
Is IONQ Inc (IONQ) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
IONQ Earning Call Sentiment
IonQ, Inc. (IONQ) Q4 2024 Earnings Call Transcript
IONQ.N
5.07%Positive
IonQ's earnings call presents mixed signals. Financial performance shows strong revenue growth and increased bookings, yet significant net losses and rising expenses raise concerns. The Q&A reveals management's avoidance of specific guidance, which is typically negative. However, partnerships and acquisitions, like with AstraZeneca and Ansys, are positive, as is the $500 million share repurchase program. Considering the company's small market cap, the stock might react more strongly, but the mixed factors balance out, leading to a neutral stock price prediction.
